Front & Back Matter.
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 1, doi. 10.1159/000544886
- Publication type:
- Article
Works matching IS 00093157 AND DT 2025 AND VI 70 AND IP 1
Results: 6
1
2
Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 26, doi. 10.1159/000541936
- By:
- Publication type:
- Article
3
Gaza's First Polio Case in 25 Years: Is Health Infrastructure Collapse Threatening Resilience?
- Published in:
- 2025
- By:
- Publication type:
- Letter
4
Downregulation of Rad51 Expression and Activity Potentiates the Cytotoxic Effect of Osimertinib in Human Non-Small Cell Lung Cancer Cells.
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 12, doi. 10.1159/000540867
- By:
- Publication type:
- Article
5
Meta-Analysis of the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced Gastric Cancer and Gastroesophageal Junction Cancer.
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 37, doi. 10.1159/000540071
- By:
- Publication type:
- Article
6
Disseminated Infection Caused by Nocardia cyriacigeorgica in Immunocompromised Patient Confirmed by Whole Genome Sequencing.
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 1, doi. 10.1159/000539977
- By:
- Publication type:
- Article